当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > Effect of mefenamic acid on bowel transit time in healthy adult volunteers.

Effect of mefenamic acid on bowel transit time in healthy adult volunteers.

Abstract：

:The effect of mefenamic acid on bowel transit time was investigated. Seven healthy adult male subjects of age 39 +/- 2.4 years (mean +/- S.E.M.) received placebo or mefenamic acid (500 mg t.d.s) orally in randomized order for five days, with a 7-day washout between studies. On the third morning after starting the drug they had a meal containing Redi-Brek and baked beans with radio-opaque markers. Small bowel transit time was measured using breath hydrogen, and whole gut transit time was measured using radio-opaque markers. The small bowel transit times were 160 min (median) with placebo and 50 min with mefenamic acid (P less than 0.05). The percentages of appearance of marker in stool within 24 h were 24.9 +/- 11.8 (mean +/- S.E.M.) with placebo and 48.9 +/- 11.7 with mefenamic acid (P less than 0.05). The times of appearance of twenty-fifth marker in stool were 41.0 +/- 4.4 h with placebo and 26.9 +/- 3.2 h with mefenamic acid (P less than 0.05). The total weights of faeces in 72 h were 500.9 +/- 96.2 g with placebo and 657.1 +/- 118.8 g with mefenamic acid (P less than 0.05). Mefenamic acid in therapeutic doses (500 mg t.d.s.) accelerated bowel transit time in healthy subjects.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Rashid MU,Bateman DN

doi

10.1111/j.1365-2036.1990.tb00488.x

subject

Has Abstract

pub_date

1990-08-01 00:00:00

pages

417-22

issue

4

eissn

0269-2813

issn

1365-2036

journal_volume

4

pub_type

临床试验,杂志文章,随机对照试验

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre.

    abstract：BACKGROUND:Hepatitis vaccination is recommended in patients with chronic liver disease. AIM:To validate Current Procedural Terminology (CPT) codes and drug codes for hepatitis vaccination in administrative databases and determine vaccination rates in hepatitis C virus (HCV)-infected patients in a single large Veterans...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03827.x

    authors： Hachem CY,Kramer JR,Kanwal F,El-Serag HB

    更新日期：2008-11-01 00:00:00

  • Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy.

    abstract：BACKGROUND:Recent evidence found probiotics could inhibit Helicobacter pylori colonization from both in vitro and in vivo studies. AIM:To systematically evaluate whether adding probiotics to anti-H. pylori regimens could improve eradication rates and reduce side effects during anti-H. pylori treatment. METHODS:Eligib...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1111/j.1365-2036.2006.03179.x

    authors： Tong JL,Ran ZH,Shen J,Zhang CX,Xiao SD

    更新日期：2007-01-15 00:00:00

  • Review article: the impact of diet on ileoanal pouch function and on the pathogenesis of pouchitis.

    abstract：BACKGROUND:There is expanding interest in the role that diet plays in ileoanal pouch function and in the pathogenesis of pouchitis. AIMS:To present a narrative review of published literature regarding the relationship of diet with pouch function and the pathogenesis of pouchitis, and to provide potentially beneficial ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.16085

    authors： Ardalan ZS,Yao CK,Sparrow MP,Gibson PR

    更新日期：2020-10-01 00:00:00

  • Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection.

    abstract：BACKGROUND:Clearance of hepatitis B surface antigen (HBsAg) indicates clinical control of hepatitis B virus (HBV) infection. However, little is known about the impact of viral genomic variations on HBsAg loss. METHODS:We explored the association between viral genomic factors and HBsAg loss in 2121HBeAg-negative patien...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13170

    authors： Tseng TC,Liu CJ,Chen CL,Yang WT,Yang HC,Su TH,Wang CC,Kuo SF,Liu CH,Chen PJ,Chen DS,Kao JH

    更新日期：2015-05-01 00:00:00

  • Review article: gastric pH -- the most relevant predictor of benefit in reflux disease?

    abstract：:Summary In patients with gastro-oesophageal reflux disease, the pH of refluxed gastric contents has a direct bearing on disease severity and oesophageal damage. A pH of 4 has been defined as a threshold below which refluxed gastric contents become injurious to the oesophagus. Studies in patients with erosive oesophagi...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2004.02140.x

    authors： Armstrong D

    更新日期：2004-10-01 00:00:00

  • Non-alcoholic fatty liver diseases and risk of colorectal neoplasia.

    abstract：BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is associated with colorectal neoplasia. Yet, NAFLD ranges from simple steatosis to steatohepatitis with advanced fibrosis. AIM:To investigate the risk of colorectal neoplasia according to the presence and severity of NAFLD. METHODS:A total of 26 540 asymptomatic a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13866

    authors： Ahn JS,Sinn DH,Min YW,Hong SN,Kim HS,Jung SH,Gu S,Rhee PL,Paik SW,Son HJ,Gwak GY

    更新日期：2017-01-01 00:00:00

  • Sedation in digestive endoscopy: the Athens international position statements.

    abstract：BACKGROUND:Guidelines and practice standards for sedation in endoscopy have been developed by various national professional societies. No attempt has been made to assess consensus among internationally recognized experts in this field. AIM:To identify areas of consensus and dissent among international experts on a bro...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 共识发展会议,杂志文章

    doi：10.1111/j.1365-2036.2010.04352.x

    authors： Cohen LB,Ladas SD,Vargo JJ,Paspatis GA,Bjorkman DJ,Van der Linden P,Axon AT,Axon AE,Bamias G,Despott E,Dinis-Ribeiro M,Fassoulaki A,Hofmann N,Karagiannis JA,Karamanolis D,Maurer W,O'Connor A,Paraskeva K,Schreiber F,

    更新日期：2010-08-01 00:00:00

  • Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial.

    abstract：BACKGROUND:The colonic mucosa is highly dependent upon the presence of luminal nutrients. This dependence is most marked in the distal colon. The major luminal nutrients are short chain fatty acids that are produced as a by-product of colonic fermentation of carbohydrates. Butyrate appears to be the short chain fatty a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.1996.d01-509.x

    authors： Steinhart AH,Hiruki T,Brzezinski A,Baker JP

    更新日期：1996-10-01 00:00:00

  • Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test.

    abstract：BACKGROUND:Guaiac-based faecal occult blood tests (g-FOBTs) are most commonly used in colorectal cancer (CRC) screening programmes. Faecal immunochemical tests (FITs) are thought to be superior. AIM:To compare performance of a g-FOBT and a quantitative FIT for detection of CRCs and advanced adenomas in a colonoscopy-c...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2036.2009.04184.x

    authors： Oort FA,Terhaar Sive Droste JS,Van Der Hulst RW,Van Heukelem HA,Loffeld RJ,Wesdorp IC,Van Wanrooij RL,De Baaij L,Mutsaers ER,van der Reijt S,Coupe VM,Berkhof J,Bouman AA,Meijer GA,Mulder CJ

    更新日期：2010-02-01 00:00:00

  • Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.

    abstract：BACKGROUND:Cross-sectional studies suggest insulin resistance is strongly associated with hepatic steatosis and fibrosis in patients with chronic hepatitis C (CHC), which might affect the efficacy of antiviral therapy. Aim To investigate retrospectively the impact of insulin resistance on treatment response in Chinese ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03823.x

    authors： Chu CJ,Lee SD,Hung TH,Lin HC,Hwang SJ,Lee FY,Lu RH,Yu MI,Chang CY,Yang PL,Lee CY,Chang FY

    更新日期：2009-01-01 00:00:00

  • Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease.

    abstract：BACKGROUND:Small bowel bacterial overgrowth is common in Crohn's disease but its treatment is not clearly defined. Metronidazole and ciprofloxacin are effective antibiotics in active Crohn's disease. AIM:To investigate the efficacy of metronidazole and ciprofloxacin in the treatment of bacterial overgrowth in patients...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2003.01800.x

    authors： Castiglione F,Rispo A,Di Girolamo E,Cozzolino A,Manguso F,Grassia R,Mazzacca G

    更新日期：2003-12-01 00:00:00

  • Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors.

    abstract：BACKGROUND:The association between myocardial infarction (MI) and co-administration of proton pump inhibitors (PPIs) and clopidogrel remains controversial. AIM:To quantify the association between concomitant use of PPIs and clopidogrel and occurrence of recurrent MI. METHODS:We conducted a case-control study within a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2010.04485.x

    authors： Valkhoff VE,'t Jong GW,Van Soest EM,Kuipers EJ,Sturkenboom MC

    更新日期：2011-01-01 00:00:00

  • Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.

    abstract：BACKGROUND:Anti-TNFα agents have revolutionised management of chronic inflammatory diseases. Paradoxically, these agents might provoke development of de novo autoimmune diseases. AIM:To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis (UC) while under treatment with ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15370

    authors： Korzenik J,Larsen MD,Nielsen J,Kjeldsen J,Nørgård BM

    更新日期：2019-08-01 00:00:00

  • Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

    abstract：BACKGROUND:Studies assessing the prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome gave contrasting results. Differences in criteria to define irritable bowel syndrome patients and methods to assess small intestinal bacterial overgrowth may explain different results. Moreover, no data exis...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2005.02690.x

    authors： Lupascu A,Gabrielli M,Lauritano EC,Scarpellini E,Santoliquido A,Cammarota G,Flore R,Tondi P,Pola P,Gasbarrini G,Gasbarrini A

    更新日期：2005-12-01 00:00:00

  • Proton pump inhibitors reduce the bioavailability of dietary vitamin C.

    abstract：BACKGROUND:The gastric juice concentration of vitamin C is reduced in subjects with elevated intragastric pH. This is probably because of the fact that the vitamin is unstable at non-acidic pH and undergoes irreversible denaturation. AIM:To determine whether elevation of intragastric pH reduces the bioavailability of ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1111/j.1365-2036.2005.02568.x

    authors： Henry EB,Carswell A,Wirz A,Fyffe V,McColl KE

    更新日期：2005-09-15 00:00:00

  • Nutritional management of patients with acute pancreatitis: a Dutch observational multicentre study.

    abstract：BACKGROUND:Following a nil per os (NPO) regimen, most patients with acute pancreatitis (AP) can resume normal oral intake within 1 week. If not tolerated, it is recommended to initiate artificial feeding, preferably by the enteral route. AIM:To evaluate the nutritional management of patients with AP in a Dutch cohort ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2036.2008.03814.x

    authors： Spanier BW,Mathus-Vliegen EM,Tuynman HA,Van der Hulst RW,Dijkgraaf MG,Bruno MJ,EARL Study Group.

    更新日期：2008-11-01 00:00:00

  • Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.

    abstract：BACKGROUND:Patients with chronic hepatitis C virus and advanced fibrosis or cirrhosis are at risk for disease progression and hepatic decompensation. AIM:To determine the effects on hepatic histology of treatment with peginterferon alfa-2a (90 or 180 mug/week) or interferon alfa-2a (3 million units three times weekly)...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2008.03620.x

    authors： Everson GT,Balart L,Lee SS,Reindollar RW,Shiffman ML,Minuk GY,Pockros PJ,Govindarajan S,Lentz E,Heathcote EJ

    更新日期：2008-04-01 00:00:00

  • Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis.

    abstract：OBJECTIVE:To determine whether flumecinol (3-trifluoromethyl-alpha-ethylbenzhydrol, Zixoryn) is effective in ameliorating pruritus of cholestasis, particularly in primary bilary cirrhosis. METHODS AND RESULTS:50 patients (46 with primary biliary cirrhosis, PBC) took oral flumecinol 600 mg or identical placebo once wee...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1994.tb00297.x

    authors： Turner IB,Rawlins MD,Wood P,James OF

    更新日期：1994-06-01 00:00:00

  • Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease.

    abstract：BACKGROUND:Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but favourable data regarding its possible use in patients with inflammatory bowel disease (IBD). AIMS:To evaluate the efficacy and safety of tacrolimus in patients with IBD...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/apt.15687

    authors： Rodríguez-Lago I,Castro-Poceiro J,Fernández-Clotet A,Mesonero F,López-Sanromán A,López-García A,Márquez L,Clos-Parals A,Cañete F,Vicuña M,Nantes Ó,Merino O,Matallana V,Gordillo J,Elorza A,Vicente R,Casanova MJ,Ferreiro-

    更新日期：2020-05-01 00:00:00

  • Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection.

    abstract：BACKGROUND:There is a need for effective and inexpensive therapy for Helicobacter pylori with good patient compliance. AIM:To evaluate a simplified twice daily schedule for treating H. pylori. METHODS:Patients infected with H. pylori (positive by CLO- and 13C-urea breath tests [UBT]) and not previously treated with a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.1999.00509.x

    authors： Mönkemüller KE,Hirschowitz BI

    更新日期：1999-05-01 00:00:00

  • Review article: intestinal failure.

    abstract：:Intestinal failure is a specific disease entity resulting from intestinal resection or disease-associated malabsorption and characterized by the inability to maintain protein-energy, fluid, electrolyte or micronutrient balance. We performed a MEDLINE search (1966-2006) to identify relevant articles, using keywords int...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.02941.x

    authors： Lal S,Teubner A,Shaffer JL

    更新日期：2006-07-01 00:00:00

  • Review article: can post-operative recurrence in Crohn's disease be prevented?

    abstract：:The decision regarding prophylactic treatment after surgery in Crohn's disease (CD) requires a good estimation of the risk of recurrence. It is also important to consider the consequences of recurrence for the patient, and the risks and benefits of treatment, bearing in mind that it will be given over a long period. S...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.03055.x

    authors： Lémann M

    更新日期：2006-10-01 00:00:00

  • Efficacy of a standard United Kingdom oral rehydration solution (ORS) and a hypotonic ORS assessed by human intestinal perfusion.

    abstract：:Human triple-lumen intestinal perfusion was used to compare water and solute absorption from the oral rehydration solution (ORS) most widely used in the United Kingdom and a new experimental hypotonic ORS (HYPO-ORS). HYPO-ORS (osmolality 210 mOsm/kg) promoted significantly greater water absorption than UK-ORS (7.03 +/...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1989.tb00249.x

    authors： Hunt JB,Elliott EJ,Farthing MJ

    更新日期：1989-12-01 00:00:00

  • Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study.

    abstract：BACKGROUND:Delta virus (HDV)-related chronic hepatitis is difficult to treat. AIMS:To evaluate the efficacy of lamivudine 100 mg daily on serum HDV-RNA, hepatitis D virus antibodies and alanine aminotransferase levels, liver histology, and on hepatitis B surface antigen seroconversion. METHODS:Thirty-one hepatitis B ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2005.02542.x

    authors： Niro GA,Ciancio A,Tillman HL,Lagget M,Olivero A,Perri F,Fontana R,Little N,Campbell F,Smedile A,Manns MP,Andriulli A,Rizzetto M

    更新日期：2005-08-01 00:00:00

  • Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.

    abstract：BACKGROUND:Up to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post-operative complications. AIM:We sought to compare 30-day postoperative ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.14459

    authors： Lightner AL,McKenna NP,Tse CS,Raffals LE,Loftus EV Jr,Mathis KL

    更新日期：2018-03-01 00:00:00

  • Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome.

    abstract：BACKGROUND:The low Fermentable Oligo-, Di- Monosaccharides, and Polyoles (FODMAP) diet is a new treatment option for irritable bowel syndrome (IBS). Experts refer to the diet as supported by high level of evidence, but an evaluation of the quality of trials is lacking. AIM:To provide a systematic review of the quality...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.14065

    authors： Krogsgaard LR,Lyngesen M,Bytzer P

    更新日期：2017-06-01 00:00:00

  • Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin.

    abstract：AIM:To evaluate and compare two 1-week low-dose triple therapies based on lansoprazole, amoxycillin and a macrolide in eradicating Helicobacter pylori. METHODS:Seventy consecutive patients, suffering from dyspeptic symptoms with H. pylori infection, were randomly allocated to one of two treatment groups: (A) (LAC; n =...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.1996.d01-533.x

    authors： Cammarota G,Tursi A,Papa A,Montalto M,Veneto G,Cuoco L,Fedeli G,Gasbarrini G

    更新日期：1996-12-01 00:00:00

  • Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.

    abstract：BACKGROUND:The treatment of HBeAg-negative chronic hepatitis B (CHB) is considered to be open-ended, with no guidelines for treatment cessation. AIM:To evaluate biochemical and virological relapse requiring retreatment in noncirrhotic HBeAg-negative CHB in patients who stopped treatment following a period of prolonged...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12908

    authors： Patwardhan VR,Sengupta N,Bonder A,Lau D,Afdhal NH

    更新日期：2014-10-01 00:00:00

  • The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.

    abstract：BACKGROUND:A large proportion (25-46%) of adults with inflammatory bowel disease in remission has symptoms of irritable bowel syndrome (IBS), which are thought to reflect ongoing inflammation. Data on paediatric inflammatory bowel disease patients are lacking. AIM:To investigate (i) the prevalence of IBS-type symptoms...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13636

    authors： Diederen K,Hoekman DR,Hummel TZ,de Meij TG,Koot BG,Tabbers MM,Vlieger AM,Kindermann A,Benninga MA

    更新日期：2016-07-01 00:00:00

  • Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume.

    abstract：BACKGROUND:Atherosclerotic cardiovascular disease is a key cause of morbidity in non-alcoholic fatty liver disease (NAFLD) but appropriate means to predict major acute cardiovascular events (MACE) are lacking. AIM:To design a bespoke cardiovascular risk score in NAFLD. METHODS:A retrospective derivation (2008-2016, 3...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15192

    authors： Abeles RD,Mullish BH,Forlano R,Kimhofer T,Adler M,Tzallas A,Giannakeas N,Yee M,Mayet J,Goldin RD,Thursz MR,Manousou P

    更新日期：2019-04-01 00:00:00